Ustekinumab. Neoplasias y otros aspectos de seguridad
Ustekinumab. Neoplasms and Other Safety Aspects
J. Santos-Juanes
, P. Coto, C. Galache
Corresponding author
Servicio de Dermatología II. Hospital Universitario Central de Asturias. Asturias. España
Read
5250
Timeswas read the article
2315
Total PDF
2935
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 120 | 207 | 327 |
| 2025 5 | 100 | 60 | 160 |
| 2025 4 | 89 | 30 | 119 |
| 2025 3 | 76 | 24 | 100 |
| 2025 2 | 70 | 22 | 92 |
| 2025 1 | 80 | 29 | 109 |
| 2024 12 | 58 | 24 | 82 |
| 2024 11 | 37 | 45 | 82 |
| 2024 10 | 62 | 37 | 99 |
| 2024 9 | 60 | 21 | 81 |
| 2024 8 | 78 | 57 | 135 |
| 2024 7 | 95 | 24 | 119 |
| 2024 6 | 59 | 28 | 87 |
| 2024 5 | 54 | 34 | 88 |
| 2024 4 | 63 | 15 | 78 |
| 2024 3 | 37 | 28 | 65 |
| 2024 2 | 35 | 28 | 63 |
| 2024 1 | 32 | 21 | 53 |
| 2023 12 | 24 | 14 | 38 |
| 2023 11 | 50 | 26 | 76 |
| 2023 10 | 21 | 8 | 29 |
| 2023 9 | 48 | 25 | 73 |
| 2023 8 | 27 | 15 | 42 |
| 2023 7 | 32 | 23 | 55 |
| 2023 6 | 21 | 24 | 45 |
| 2023 5 | 15 | 9 | 24 |
| 2023 4 | 19 | 15 | 34 |
| 2023 3 | 27 | 22 | 49 |
| 2023 2 | 25 | 12 | 37 |
| 2023 1 | 26 | 21 | 47 |
| 2022 12 | 23 | 24 | 47 |
| 2022 11 | 27 | 33 | 60 |
| 2022 10 | 28 | 36 | 64 |
| 2022 9 | 25 | 30 | 55 |
| 2022 8 | 23 | 26 | 49 |
| 2022 7 | 22 | 33 | 55 |
| 2022 6 | 21 | 22 | 43 |
| 2022 5 | 34 | 33 | 67 |
| 2022 4 | 29 | 30 | 59 |
| 2022 3 | 29 | 48 | 77 |
| 2022 2 | 22 | 19 | 41 |
| 2022 1 | 26 | 31 | 57 |
| 2021 12 | 30 | 37 | 67 |
| 2021 11 | 33 | 36 | 69 |
| 2021 10 | 32 | 42 | 74 |
| 2021 9 | 34 | 43 | 77 |
| 2021 8 | 26 | 36 | 62 |
| 2021 7 | 24 | 27 | 51 |
| 2021 6 | 19 | 20 | 39 |
| 2021 5 | 19 | 32 | 51 |
| 2021 4 | 39 | 66 | 105 |
| 2021 3 | 40 | 39 | 79 |
| 2021 2 | 28 | 32 | 60 |
| 2021 1 | 31 | 21 | 52 |
| 2020 12 | 14 | 18 | 32 |
| 2020 11 | 14 | 15 | 29 |
| 2020 10 | 18 | 3 | 21 |
| 2020 9 | 21 | 6 | 27 |
| 2020 8 | 24 | 14 | 38 |
| 2020 7 | 13 | 10 | 23 |
| 2020 6 | 19 | 14 | 33 |
| 2020 5 | 36 | 30 | 66 |
| 2020 4 | 25 | 20 | 45 |
| 2020 3 | 11 | 13 | 24 |
| 2020 2 | 0 | 3 | 3 |
| 2020 1 | 0 | 1 | 1 |
| 2019 12 | 0 | 10 | 10 |
| 2019 11 | 0 | 16 | 16 |
| 2019 10 | 0 | 7 | 7 |
| 2019 9 | 0 | 4 | 4 |
| 2019 8 | 0 | 3 | 3 |
| 2019 7 | 0 | 8 | 8 |
| 2019 6 | 0 | 1 | 1 |
| 2019 5 | 0 | 14 | 14 |
| 2019 4 | 0 | 7 | 7 |
| 2019 2 | 0 | 2 | 2 |
| 2018 12 | 0 | 3 | 3 |
| 2018 11 | 0 | 2 | 2 |
| 2018 10 | 0 | 2 | 2 |
| 2018 2 | 12 | 5 | 17 |
| 2018 1 | 3 | 4 | 7 |
| 2017 12 | 14 | 7 | 21 |
| 2017 11 | 10 | 5 | 15 |
| 2017 10 | 8 | 2 | 10 |
| 2017 9 | 6 | 5 | 11 |
| 2017 8 | 7 | 3 | 10 |
| 2017 7 | 6 | 2 | 8 |
| 2017 6 | 11 | 11 | 22 |
| 2017 5 | 18 | 3 | 21 |
| 2017 4 | 18 | 7 | 25 |
| 2017 3 | 21 | 2 | 23 |
| 2017 2 | 12 | 6 | 18 |
| 2017 1 | 13 | 3 | 16 |
| 2016 12 | 16 | 4 | 20 |
| 2016 11 | 23 | 6 | 29 |
| 2016 10 | 26 | 12 | 38 |
| 2016 9 | 24 | 12 | 36 |
| 2016 8 | 26 | 9 | 35 |
| 2016 7 | 28 | 7 | 35 |
| 2016 6 | 1 | 7 | 8 |
| 2016 5 | 0 | 13 | 13 |
| 2016 4 | 0 | 2 | 2 |
| 2016 3 | 0 | 3 | 3 |
| 2016 2 | 0 | 4 | 4 |
| 2016 1 | 0 | 14 | 14 |
| 2015 12 | 2 | 13 | 15 |
| 2015 11 | 3 | 16 | 19 |
| 2015 10 | 0 | 9 | 9 |
| 2015 9 | 2 | 11 | 13 |
| 2015 8 | 9 | 4 | 13 |
| 2015 7 | 10 | 2 | 12 |
| 2015 6 | 19 | 7 | 26 |
| 2015 5 | 34 | 14 | 48 |
| 2015 4 | 27 | 13 | 40 |
| 2015 3 | 20 | 11 | 31 |
| 2015 2 | 23 | 13 | 36 |
| 2015 1 | 18 | 15 | 33 |
| 2014 12 | 12 | 12 | 24 |
| 2014 11 | 18 | 16 | 34 |
| 2014 10 | 27 | 22 | 49 |
| 2014 9 | 0 | 2 | 2 |
| 2014 5 | 2 | 0 | 2 |
| 2014 4 | 1 | 0 | 1 |
| 2014 1 | 0 | 1 | 1 |
| 2013 12 | 2 | 0 | 2 |
| 2013 9 | 1 | 1 | 2 |
| 2013 6 | 1 | 1 | 2 |
| 2013 5 | 1 | 1 | 2 |
| 2013 4 | 1 | 1 | 2 |
| 2013 2 | 0 | 1 | 1 |
| 2013 1 | 0 | 1 | 1 |
Show all
